ONC — BeOne Medicines Ltd.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1651308 · Switzerland
Last close
$413.26
Market Cap
$43.55B
52W High
$424.73
52W Low
$253.95
ADV30
423,160
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,889,815,000 1,672,919,000 418,675,000 384,706,000 9,875,925,000 5,781,128,000 4,055,531,000
Jun 2026 1,705,071,000 1,530,541,000 325,047,000 237,007,000 9,175,615,000 5,098,041,000 4,001,617,000
Mar 2026 1,513,438,000 1,346,223,000 249,902,000 227,357,000 8,553,619,000 4,791,676,000 3,793,177,000
Dec 2025 1,498,170,000 1,355,748,000 185,035,000 66,502,000 8,188,573,000 4,547,530,000 3,827,379,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,590,210,000
Investing CF
$-168,958,000
Financing CF
$261,703,000
CapEx
$-161,480,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$7.80
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-7,470,833,000
Inventory
$807,922,000
Receivables
$1,149,113,000
ST Investments
—
EBIT TTM
$1,310,054,000
Pretax Income TTM
$1,131,275,000
Interest Exp TTM
$131,397,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,606,494,208
EBITDA
$1,328,759,040
Free Cash Flow
$1,026,932,608
Enterprise Value
$42,765,664,256
Total Cash
$5,781,128,192
Total Debt
$2,061,346,944
Shares Out
105,375,675
Trailing EPS
$7.80
Book Value
$51.01
ROE
18.4%
ROA
8.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 5,343,033,000 447,136,000 286,933,000 8,188,573,000 3,827,379,000 4,361,194,000 1,127,580,000
Dec 2024 3,810,241,000 -568,199,000 -644,786,000 5,920,910,000 2,588,688,000 3,332,222,000 -140,631,000
Dec 2023 2,458,779,000 -1,207,736,000 -881,708,000 5,805,275,000 2,267,948,000 3,537,327,000 -1,157,453,000
Dec 2022 1,415,921,000 -1,789,665,000 -2,003,815,000 6,379,290,000 1,995,935,000 4,383,355,000 -1,496,619,000

TTM Snapshot

Revenues TTM
$6,128,963,000
NetIncome TTM
$655,707,000
OpCashFlow TTM
—
Assets (Latest)
$9,175,615,000
Forward EPS
$11.02

Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $370.00 · spot: $403.60 · call volume: 288 · put volume: 20
Expected Move to 2027-05-21: ±$89.25 (22.11%) — implied range $314.35 – $492.85 · ATM straddle on $400.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD $49.73B $42.62 —
ZTS Zoetis Inc. $33.92B $83.48 —
GMAB GENMAB A/S $31.95B $51.96 —
RPRX Royalty Pharma plc $30.58B $68.68 —
ROIV Roivant Sciences Ltd. $28.05B $38.71 —

News headlines (Yahoo Finance, 1h cache)

CLL Society and BeOne Medicines Announce Expanded Partnership to Advance Education and Support Across the CLL/SLL Community
2026-11-17 11:00 · Yahoo
Top 3 Healthcare Stocks To Watch In November 2026
2026-11-07 19:13 · Yahoo
BeOne Medicines Q3 Earnings Call Highlights
2026-11-06 13:14 · Yahoo
BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion in U.S. ...
2026-11-05 23:19 · Yahoo
Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics
2026-11-05 21:30 · Yahoo
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
2026-11-05 21:22 · Yahoo
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake
2026-11-05 17:18 · Yahoo
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
2026-11-05 11:00 · Yahoo
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma
2026-11-04 14:13 · Yahoo
Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics
2026-11-03 13:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.